Immunogenicity evaluation of Gam-COVID-Vac (Sputnik V)

In November 2020, the Armed Forces of the Russian Federation began mass immunisation of the personnel with Gam-COVID-Vac (Sputnik V), the first Russia vaccine against the new coronavirus infection (COVID-19). Thus, it became necessary to assess post-vaccination antibody levels and the duration and intensity of humoral immunity to COVID-19.

The aim of the study was to investigate the immunogenicity and efficacy of Gam-COVID-Vac in military medical staff after vaccination.

Materials and methods: the authors determined the presence of specific antibodies in the serum of individuals immunised with Gam-COVID-Vac (477 volunteers) and COVID-19 convalescents (73 patients), using virus neutralisation (VN), enzyme-linked immunosorbent assay (ELISA) with reagent kits by several manufacturers, and immunoblotting. The results of the study were evaluated using analysis of variance.

Results: VN detected virus neutralising antibodies in 90.7% of vaccinated subjects; ELISA, in 95.4%. Both VN and ELISA showed lower antibody levels in the vaccinated over 50 years of age. ELISA demonstrated a significantly higher concentration of anti-SARS-CoV-2 spike IgG in the Gam-COVID-Vac group than in the COVID-19 convalescent group. The correlation between antibody detection results by VN and ELISA was the strongest when the authors used their experimental reagent kit for quantitative detection of virus neutralising antibodies by competitive ELISA with the recombinant human ACE2 receptor. Having analysed the time course of neutralising antibody titres, the authors noted a significant, more than two-fold decrease in geometric means of the titres three months after administration of the second vaccine component.

Conclusions: the subjects vaccinated with Gam-COVID-Vac gain effective humoral immunity to COVID-19. The decrease in titres indicates the need for revaccination in 6 months.

1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. https://doi.org/10.1016/S0140-6736(21)00234-8

2. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97. https://doi.org/10.1016/S0140-6736(20)31866-3

3. Lvov DK, ed. Guide to Virology: Viruses and Viral Infections of Humans and Animals. Moscow: Medicinskoe Informatsionnoe Agentstvo; 2013 (In Russ.)]

4. Bundschuh C, Egger M, Wiesinger K, Gabriel C, Clodi M, Mueller T, Dieplinger B. Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma. Clin Chim Acta. 2020;509:79–82. https://doi.org/10.1016/j.cca.2020.05.047

5. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody detection and dynamic characteristics in patients with Coronavirus Disease 2019. Clin Infect Dis. 2020;71(8):1930–4. https://doi.org/10.1093/cid/ciaa461

6. Ginsburg NN, Kasymov KT, Altshtein AD. Comparative study of various methods of titration of virus-neutralising antibodies to poliomyelitis virus in tissue culture. Voprosy Virusologii = Problems of Virology. 1960;5:20–5 (In Russ.)]

7. Pshenichnov VA, Semenov BF, Zezerov EG, eds. Standardization of Virological Research Methods. Moscow: Meditsina; 1974 (In Russ.)]

8. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;28(3):475–85. https://doi.org/10.1016/j.chom.2020.06.021

9. Kim B. Western blot techniques. Methods Mol Biol. 2017;1606:133–9. https://doi.org/10.1007/978-1-4939-6990-6_9

10. Towbin H, Gordon J. Immunoblotting and dot immunobinding – current status and outlook. J Immunol Methods. 1984;72(2):313–40. https://doi.org/10.1016/0022-1759(84)90001-2

11. Ashmarin IP, Vorobyov AA. Statistical Methods in Microbiological Research. Leningrad: Gosudarstvennoe Izdanie Meditsinskoy Literatury; 1962 (In Russ.)]

12. Genes VS. Some Simple Methods for Cybernetic Processing of Data from Diagnostic and Physiological Studies. Moscow; 1967 (In Russ.)]

13. Urbakh VYu. Statistical Analysis in Biological and Medical Research. Moscow: Meditsina; 1975 (In Russ.)]

14. Nam M, Seo JD, Moon HW, Kim H, Hur M, Yun YM. Evaluation of humoral immune response after SARS-CoV-2 vaccination using two binding antibody assays and a neutralizing antibody assay. Microbiol Spectr. 2021;9(3):e0120221. https://doi.org/10.1128/Spectrum.01202-21

15. Mahmoud SA, Ganesan S, Naik S, Bissar S, Zamel IA, Warren KN, et al. Serological assays for assessing postvaccination SARS-CoV-2 antibody response. Microbiol Spectr. 2021;9(2):e0073321. https://doi.org/10.1128/Spectrum.00733-21

16. Hoshida S, Koeda N, Hattori H, Tanaka M, Tanaka I, Fukui H, et al. Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka. BMC Infect Dis. 2022;22(1):709. https://doi.org/10.1186/s12879-022-07695-7